Table 1.
Historical of MS drug approval from FDA and EMA.
| DRUGS | FDA DATE OF APPROVAL | EMA DATE OF APPROVAL |
|---|---|---|
| Interferon beta 1b | 23 Jul 1993 | 30 Nov 1995 |
| Interferon beta 1a 30 μg | 17 May 1996 | 13 Mar 1997 |
| Glatiramer acetate | 20 Dec 1996 | *** |
| Interferon beta 1a 22 μg | 07 Mar 2002 | 04 May 1998 |
| Interferon beta 1a 44 μg | 07 Mar 2002 | 04 May 1998 |
| Natalizumab | 23 Nov 2004 | *** |
| Fingolimod | 21 Sep 2010 | *** |
| Teriflunomide | 12 Sep 2012 | 26 Aug 2013 |
| Dimethyl fumarate | 27 Mar 2013 | 30 Jan 2014 |
| Alemtuzumab | Under analysis | 12 Sep 2013 |
| Daclizumab**** | Not submitted for approval | Not submitted for approval |
| Ocrelizumab | Not submitted for approval | Not submitted for approval |
| Laquinimod | Not submitted for approval | Not submitted for approval |
Notes: *FDA: Food and Drug Administration. **EMA: European Medicines Agency. ***Each country has determined specific drug approval, with different dates; this information is not available on the EMA website. ****Daclizumab has already been approved for prophylaxis against organ rejection among kidney transplant recipients, but not for MS yet.